Mooren ulcer: An immunopathologic study

Cornea

Volumn 25, Issue 6, 2006, Pages 667-673

  Kafkala, Chrysanthi ^a   Choi, John ^a   Zafirakis, Panayotis ^a   Baltatzis, Stefanos ^b   Livir Rallatos, Charalampos ^a   Rojas, Blanca ^a   Foster, C Stephen ^a,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b KAT HOSPITAL   (Greece)

^c Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

Adhesion molecules; Co stimulatory molecules; Mooren ulcer

Indexed keywords

B7 ANTIGEN; CD1 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONJUNCTIVA EPITHELIUM; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; CORNEA RODENT ULCER; CORNEA STROMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CD4-CD8 RATIO; CELL ADHESION MOLECULES; CHRONIC DISEASE; CONJUNCTIVA; CORNEAL ULCER; EPITHELIUM; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOCYTES, MONONUCLEAR; UP-REGULATION;

EID: 33750549938     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000214216.75496.7e     Document Type: Article

References (43)

1. Foster CS. Mooren's ulcer. In: Foster CS, Azar DT, Dohlman CH, eds. Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:551-557.
2. Foster CS, Kenyon KR, Greiner J, et al. The immunopathology of Mooren's ulcer. Am J Ophthalmol. 1979;88:149-159.
3. Ye J, Chen J, Kim JC, et al. Bone marrow-derived cells are present in Mooren's ulcer. Ophthalmic Res. 2004;36:151-155.
4. Brown SI, Mondino BJ, Rabin BS. Autoimmune phenomenon in Mooren's ulcer. Am J Ophthalmol. 1976;82:835-840.
5. Gottsch JD, Liu SH, Minkovitz JB, et al. Autoimmunity to a cornea-associated stromal antigen in patients with Mooren's ulcer. Invest Ophthalmol Vis Sci. 1995;36:1541-1547.
6. Foster CS. Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer. Ophthalmology. 1985;92:1436-1439.
7. Zhao JC, Jin XY. Treatment of severe Mooren's ulcer with cyclosporin A eyedrops. Chin Med J (Engl). 1992;105:406-409.
8. Kluger MS. Vascular endothelial cell adhesion and signaling during leukocyte recruitment. Adv Dermatol. 2004;20:163-201.
9. Springer TA. Adhesive receptors of the immune system. Nature. 1990;346:425-434.
10. Beviacqua MP, Nelson RM. Selectins. J Clin Invest. 1993;91:379-387.
11. Bochner BS, Schleimer RP. The role of adhesion molecule in human eosinophil and basophil recruitment. J Allergy Clin Immunol. 1994;94:427-438.
12. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2001;2:203-209.
13. Bluestone JA. New perspectives of CD28-B7- mediated T cell costimulation. Immunity. 1995;2:555-559.
14. Crow MK. Costimulatory molecules and T-cell-B-cell interactions. Rheum Dis Clin North Am. 2004;30:175-191.
15. Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum. 1997;40:991-1004.
16. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
17. Lozada C, Levin RI, Huie M, et al. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA. 1995;92:8378-8382.
18. Yellin MJ, Brett J, Baum D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med. 1995;182:1857-1864.
19. Silber A, Newman W, Reimann KA, et al. Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. Lab Invest. 1994;70:163-175.
20. Philipp W, Gottinger W. Leukocyte adhesion molecules in diseased corneas. Invest Ophthalmol Vis Sci. 1993;34:2449-2459.
21. Koch AE, Burrows JC, Haines GK, et al. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 1991;64:313-320.
22. Picker LJ, Kishimoto TK, Smith CW, et al. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 1991;349:796-799.
23. Bacon AS, McGill JI, Anderson DF, et al. Adhesion molecules and relationship to leukocyte levels in allergic eye disease. Invest Ophthalmol Vis Sci. 1998;39:322-330.
24. Abu el-Asrar AM, Geboes K, al-Kharashi S, et al. Adhesion molecules in vernal keratoconjunctivitis. Br J Ophthalmol. 1997;81:1099-1106.
25. Whitcup SM, Kozhich AT, Lobanoff M, et al. Blocking both E-selectin and P-selectin inhibits endotoxin-induced leukocyte infiltration into the eye. Clin Immunol Immunopathol. 1997;83:45-52.
26. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577-584.
27. Pober J, Cotran RS. What can be learned from the expression of endothelial adhesion molecules in tissues? Lab Invest. 1991;64:301-305.
28. Gao JX, Issekutz AC. Expression of VCAM-1 and VLA-4 dependent T-lymphocyte adhesion to dermal fibroblasts stimulated with proinflammatory cytokines. Immunology. 1996;89:375-383.
29. Maenpaa A, Kovanen PE, Paetau A, et al. Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas. Acta Neuropathol (Berl). 1997;94:216-225.
30. Lin Y, Kirby JA, Browell DA, et al. Renal allograft rejection: expression and function of VCAM-1 on tubular epithelial cells. Clin Exp Immunol. 1993;92:145-151.
31. Walton LJ, Thornhill MH, Farthing PM. VCAM-1 and ICAM-1 are expressed by Langerhans cells, macrophages and endothelial cells in oral lichen planus. J Oral Pathol Med. 1994l;23:262-268.
32. Rice GE, Munro JM, Corless C, et al. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol. 1991;138:385-393.
33. Buck CA. Immunoglobulin superfamily: structure, function and relationship to other receptor molecules. Semin Cell Biol. 1992;3:179-188.
34. Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum. 1993;36:147-157.
35. Uchio E, Kijima M, Tanaka S, et al. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci. 1994;35:2626-2631.
36. Tesavibul N, Dorfman D, Sangwan VS, et al. Costimulatory molecules in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1998;39:982-988.
37. Balsa A, Dixey J, Sansom DM, et al. Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Br J Rheumatol. 1996;35:33-37.
38. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994;265:1225-1227.
39. Nishikawa K, Linsley PS, Collins AB, et al. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol. 1994;24:1249-1254.
40. Razi-Wolf Z, Galvin F, Gray G, et al. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc Natl Acad Sci USA. 1993;90:11182-11186.
41. Liossis SN, Sfikakis PP. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs. 2004;18:95-102.
42. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994;37:992-999.
43. Dedrick RL, Bodary S, Garovoy MR. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin Biol Ther. 2003;3:85-95.